Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, recently announced that it has raised some CHF 4.5m to date and attracted new board member and investor David Urech. Other current investors include Kickfund and Zürcher Kantonalbank. Aukera discovered a highly selective RAPTOR inhibitor modulating the mTORC1 signaling network – a new approach to selectively tackling a proven target with the potential for greater efficacy and favorable safety.

VISCHER advises Aukera on all Swiss-law matters. The team includes Christian Wyss (Partner, Corporate/M&A) and Luzius Zumstein (Managing Associate, Corporate/M&A).

Author: Luzius Zumstein